Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 14 years of Total Non-Current Liabilities data on file, last reported at $24.6 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 44.05% year-over-year to $24.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.6 million (down 44.05% YoY) and the FY2025 annual result came in at $24.6 million, down 44.05% from the prior year.
• Total Non-Current Liabilities fell to $24.6 million in Q4 2025, from $43.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $56.8 million in Q2 2024 to a low of $4.0 million in Q2 2022.
• A 5-year average of $29.0 million and a median of $25.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 536.24% — and 2025, when it slumped 44.05%.
• Tracing FENC's Total Non-Current Liabilities over 5 years: stood at $5.0 million in 2021, then soared by 399.18% to $24.9 million in 2022, then climbed by 24.23% to $30.9 million in 2023, then soared by 41.92% to $43.9 million in 2024, then tumbled by 44.05% to $24.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $24.6 million (Q4 2025), $43.9 million (Q3 2025), and $43.9 million (Q2 2025), per Business Quant data.